|
全球用于临床治疗阿尔茨海默病的药物目前只有寥寥数款，在17年没有新药上市后，最近中国原创治疗阿尔茨海默病新药率先获批。
11月2日国家药品监督管理局有条件批准了甘露特钠胶囊(商品名“九期一”)上市注册申请。
各国都在为治疗老年痴呆努力，前不久美国百建公司宣布一款治疗阿尔茨海默病新药已经通过临床测验正待FDA批准，有望量产。老年痴呆有治了?世界首款阿兹海默药有望量产
而中国原创治疗阿尔茨海默病新药率先获批上市，不仅填补世界空白，也引发了外媒关注。
Authorities in China have approved a drug for the treatment of Alzheimer's disease, the first new medicine with the potential to treat the cognitive disorder in 17 years.
中国已经批准了一种用于治疗阿尔茨海默病的新药物，这是17年来首个获批，可能可以治疗认知障碍疾病的新药。
The seaweed-based drug, called Oligomannate, can be used for the treatment of mild to moderate Alzheimer'.
这个海藻中提取有效物质的新药，可改善轻、中度阿尔茨海默病患者认知功能障碍。
▲China approves seaweed-based Alzheimer's drug. It's the first new one in 17 years Via CNN
研发团队在《细胞研究》(Cell Research)杂志上发表论文，揭示了GV-971抑制阿尔茨海默症的作用机理和海藻有关。
In September, the team behind the new drug, led by Geng Meiyu at the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences, said they were inspired to look into seaweed due to the relatively low incidence of Alzheimer's among people who consume it regularly.
今年9月，中国科学院上海药物研究耿美玉带领的研发团队称，他们受到启发，研究海藻和老年痴呆症的关联。因为经常食用海带和海藻一类食物的人，发生阿尔茨海默病的概率相对较低。
In a paper in the journal Cell Research, Geng's team described how a sugar contained within seaweed suppresses certain bacteria contained in the gut which can cause neural degeneration and inflammation of the brain, leading to Alzheimer's.
发布在《细胞研究》上的论文揭示了从海藻中提取的一种糖类分子可以抑制一种肠道菌群，这种菌群会导致神经病变和脑部炎症，从而引发阿尔茨海默病。
▲China approves seaweed-based Alzheimer's drug. It's the first new one in 17 years Via CNN
另据每日经济新闻报道，绿谷制药方面表示，公司已做好生产、销售的各项准备，药品年内投放市场。
The company said Oligomannate will be available in China "very soon," and it is currently seeking approval to market it abroad, with plans to launch third-phase clinical trials in the US and Europe in early 2020.
该公司表示甘露特钠胶囊将会“很快”在中国上市，目前正寻求批准在国外销售，并计划于2020年初在美国和欧洲启动第三阶段临床试验。
▲China approves seaweed-based Alzheimer's drug. It's the first new one in 17 years Via CNN
目前全球约有5000万阿尔兹海默患者，中国患者约占20%。阿尔茨海默病是以1906年发现这种疾病的神经病理学家Alois Alzheimer的名字命名的。到目前为止，世界范围内制药公司的研究进展缓慢。
In October, US pharmaceutical giant Biogen said it would pursue Food and Drug Administration (FDA) approval for an experimental treatment called aducanumab, after announcing in March it was canceling a large clinical trial for the drug.
美国制药巨头百健公司也在研发一种叫aducanumab的阿尔茨海默病治疗药物。继3月宣布将临床试验后不理想后，今年10月，百健公司宣布实验获得进展，将寻求美国食品和药物管理局(FDA)获批新药。
Johnson & Johnson, Merck, Pfizer and Eli Lilly have all previously abandoned projects to develop a drug for Alzheimer's after unsatisfactory clinical data.
此前由于临床数据不理想，强生、默克、辉瑞和礼来等公司都放弃了阿尔茨海默病药物的研发项目。
▲China approves seaweed-based Alzheimer's drug. It's the first new one in 17 years Via CNN
外国网友纷纷为中国科研人员的创新成果点赞：
Ok American doctors stay looking into it. Remember some of our medicines they discovered first.
好吧，美国的医生看看。记得有些药是他们(中国)先研制的。
Thousands of attempts have resulted on this drug. Hopefully, it will cure the patient in an expected way.
无数次努力尝试才有了这款新药的诞生，希望可以对患者有效。
Amazing! So what have we been doing? Of course big pharmaceutical wants to make every penny from the sick.
太棒了!所以看看我们做了些啥?各大医药公司只想着从患者身上赚取更多的钱。
关注生态文明
馈赠名家字画 |
